Green light, or go slow: What FDA's new draft guidance means for social media in pharma

Click here to register 

Date: Thursday, March 13, 2014
Time: 2:00 PM ET / 11:00 AM PT

While not the last word on the subject, the agency's latest social media guidance was a good step forward. This informative webcast is designed to dissect the guidance and help brand directors and communication managers, whether currently engaging in social media or looking to do so, apply the rules now.

Experts from pharma marketing and digital media will leverage real scenarios to provide insights on the draft guidance, as the agency seeks to modernize its regulations for social and offer ways for pharma to communicate in the medium.

The event will explain the impact in the following areas:

-Handling of user-generated content

-Influence over third-party content

-New rules on submission of real-time content

-Responsibilities of those acting on the company's behalf

-Practicalities surrounding social media workflow

-Impact on expectations from consumers and HCPs

-What's next

Sponsored by: 

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.